These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27547755)

  • 1. Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks.
    Xu J; Wang P; Yang H; Zhou J; Li Y; Li X; Xue W; Yu C; Tian Y; Zhu F
    Biomed Res Int; 2016; 2016():2509385. PubMed ID: 27547755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
    Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F
    PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinases: From targets to anti-cancer drugs.
    Cruzalegui F
    Ann Pharm Fr; 2010 Jul; 68(4):254-9. PubMed ID: 20637357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
    Latham BD; Geffert RM; Jackson KD
    Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets.
    Mayburd AL; Golovchikova I; Mulshine JL
    Bioinformatics; 2008 Feb; 24(3):389-95. PubMed ID: 17925305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic analysis of FDA-approved anticancer drugs.
    Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
    Wu P; Nielsen TE; Clausen MH
    Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in kinase drug discovery: targets, indications and inhibitor design.
    Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
    Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.
    Ayala-Aguilera CC; Valero T; Lorente-Macías Á; Baillache DJ; Croke S; Unciti-Broceta A
    J Med Chem; 2022 Jan; 65(2):1047-1131. PubMed ID: 34624192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early accelerated approval for highly targeted cancer drugs.
    Chabner BA
    N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
    [No Abstract]   [Full Text] [Related]  

  • 13. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose of reality for rational therapies.
    Nat Biotechnol; 2005 Mar; 23(3):267. PubMed ID: 15765066
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel therapeutic targets.
    Farley J; Birrer MJ
    Cancer Treat Res; 2009; 149():63-84. PubMed ID: 19763431
    [No Abstract]   [Full Text] [Related]  

  • 16. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
    Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
    Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
    Warner SL; Gray PJ; Von Hoff DD
    Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-drug associations: a complex system.
    Dalkic E; Wang X; Wright N; Chan C
    PLoS One; 2010 Apr; 5(4):e10031. PubMed ID: 20368808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network analysis of FDA approved drugs and their targets.
    Ma'ayan A; Jenkins SL; Goldfarb J; Iyengar R
    Mt Sinai J Med; 2007 Apr; 74(1):27-32. PubMed ID: 17516560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.